An economist by training with a lengthy career in medtech and pharma, Benedikt von Braunmühl is well placed to provide a candid view of the contract development and manufacturing market. He took the helm of Rentschler Biopharma SE in September 2023 after the departure of Frank Mathias earlier in the year, who is now CEO of Oxford BioMedica plc.
Prior to joining Rentschler Biopharma, von Braunmühl was CEO of HMNC Brain Health where he transformed a research-focused organization into a clinical-stage biopharma company